January 30, 2024 02:37 PM ESTUpdated 03:21 PM
Pharma
FDA+

FDA re­jects mo­tion sick­ness drug from De­fend­er Phar­ma

Katherine Lewin

News Reporter

Gov­ern­ment-part­nered De­fend­er Phar­ma­ceu­ti­cals re­ceived an FDA re­jec­tion Tues­day for its mo­tion sick­ness pre­ven­tion drug.

“We plan on sched­ul­ing a for­mal meet­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times